Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

NewsGuard 100/100 Score

The stroma of the choroid plexus is one of the locations within the central nervous system (CNS) that serves as a shelter for tumor cells, allowing them to elude chemotherapy and potentially cause subsequent relapses in childhood acute lymphoblastic leukaemia, according to research led by the Complutense University of Madrid (UCM).

The choroid plexus is a structure located in the ventricles of the brain and is responsible for the production of cerebrospinal fluid. Although leukemia cells are primarily located in the bone marrow, they are also capable of spreading to other areas of the body and show a particular propensity to infiltrate the CNS.

The fact that relapses continued to occur in the CNS despite prophylactic treatment led us to suspect that some cells might remain hidden in small, practically undetectable groups elsewhere, and could be responsible for subsequent relapses."

Ángeles Vicente, Researcher, Department of Cell Biology, UCM School of Medicine

Besides identifying the hiding place, the study published in the Journal of Pathology also reveals how leukaemia cells elude chemotherapy: by interacting with stroma cells in the choroid plexus, modifying the microenvironment to ensure their own survival.

The Niño Jesús Hospital in Madrid and the Autonomous University of Chihuahua (Mexico) were also involved in the research.

A breakthrough for more effective treatment

To carry out the study, the researchers infused leukaemic cells from patients into immunodeficient mice and then used immunofluorescence and electron microscopy to determine the cerebral location of metastatic tumor cells in the CNS, successfully identifying the site in the choroid plexus.

This in vivo technique was combined with in vitro assays to study the cell interactions that take place between leukemia cells and choroid plexus stroma cells and their effects on chemoresistance.

About 15-20% of paediatric patients with acute lymphoblastic leukemia are not cured, and relapses in the CNS are the main cause of morbidity and mortality from the disease in the paediatric population.

"Studies like ours could be essential to design more effective therapeutic strategies in the future aimed at preventing tumor cells from colonising niches in the CNS or eliminating the cells that have already established themselves in these sites. This would represent a breakthrough in treatment of the disease, reducing relapses and further increasing the chances of a cure", predicted Lidia Martínez Fernández de Sevilla, a postdoctoral researcher in the Department of Cell Biology and the first named author of the study.

The research focused on childhood acute lymphoblastic leukemia because the group only works with paediatric samples, but experts believe it is feasible that leukemia cells might use the same hiding places in adults --where 5% of relapses are related to the CNS-- as they do in children.

Source:
Journal reference:

Fernández-Sevilla, L.M., et al. (2020) The choroid plexus stroma constitutes a sanctuary for paediatric B-cell precursor acute lymphoblastic leukaemia in the central nervous system. The Journal of Pathology. doi.org/10.1002/path.5510.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Combined chemohormonal therapy for locally advanced prostate cancer offers extended control of PSA levels